Frontier Innovation and Techno-Optimism
Michael Chambers co-founded Aldevron while studying chemistry, microbiology, and biotechnology at North Dakota State University. Aldevron evolved from a small NDSU lab into a cornerstone of the global genetic medicine industry. Today, Aldevron manufactures nucleic acids, recombinant enzymes, and products used in molecular diagnostics, cell and gene therapies, gene editing, and vaccines.
Michael served as Aldevron's CEO until 2020 when he transitioned to Executive Chairman. In 2021, Danaher Corporation (DHR) acquired Aldevron for $9.6 billion. Michael continues to work at Aldevron, his family office, Hive & Colony, and the Centurion Foundation. He is a board member of the Whitehead Institute at MIT and Sarepta Therapeutics (SRPT). Michael's wife and five daughters split time between Fargo and Boston.
Registration
Meal reservations now open to everyone in the Claremont Colleges.